118 related articles for article (PubMed ID: 10052714)
1. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study.
Oivanen TM; Kellokumpu-Lehtinen P; Koivisto AM; Koivunen E; Palva I
Eur J Haematol; 1999 Feb; 62(2):109-16. PubMed ID: 10052714
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).
Keldsen N; Bjerrum OW; Dahl IM; Drivsholm A; Ellegaard J; Gadeberg O; Gimsing P; Grønvold T; Hansen MM; Hippe E
Eur J Haematol; 1993 Aug; 51(2):80-5. PubMed ID: 8370422
[TBL] [Abstract][Full Text] [Related]
3. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
4. Improved long-term survival in multiple myeloma. Finnish Leukaemia Group.
Eur J Haematol; 1989 Nov; 43(5):385-8. PubMed ID: 2612611
[TBL] [Abstract][Full Text] [Related]
5. Response rate and survival after conventional chemotherapy for multiple myeloma by hospitals with different inclusion rates of patients to the trials. A Finnish Leukemia Group study.
Oivanen T; Kellokumpu-Lehtinen P; Koivisto AM; Koivunen E
Eur J Haematol; 1999 Oct; 63(4):225-30. PubMed ID: 10530410
[TBL] [Abstract][Full Text] [Related]
6. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
7. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
[TBL] [Abstract][Full Text] [Related]
8. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study.
Eur J Haematol; 2000 Aug; 65(2):123-7. PubMed ID: 10966173
[TBL] [Abstract][Full Text] [Related]
9. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group.
Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E; Kilpi H
Eur J Haematol; 1989 Oct; 43(4):328-31. PubMed ID: 2583258
[TBL] [Abstract][Full Text] [Related]
10. VAD followed by VMCP: an alternative regimen for multiple myeloma.
Wadhwa J; Kumar L; Kochupillai V
Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy of multiple myeloma].
Uzuka Y; Saito Y; Ito T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in multiple myeloma: a Finnish Leukaemia Group study.
Br J Haematol; 1999 Jun; 105(4):942-7. PubMed ID: 10554804
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
Palva IP; Ala-Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E
Eur J Haematol; 1993 Aug; 51(2):98-101. PubMed ID: 8370425
[TBL] [Abstract][Full Text] [Related]
15. Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.
Scand J Haematol; 1985 Aug; 35(2):205-9. PubMed ID: 3901244
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
[TBL] [Abstract][Full Text] [Related]
17. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
[TBL] [Abstract][Full Text] [Related]
18. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
19. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
20. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
Davies FE; Forsyth PD; Rawstron AC; Owen RG; Pratt G; Evans PA; Richards SJ; Drayson M; Smith GM; Selby PJ; Child JA; Morgan GJ
Br J Haematol; 2001 Mar; 112(3):814-9. PubMed ID: 11260088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]